Basics Akebia Therapeutics, Inc. Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. IPO Date: March 24, 2018 Sector: Healthcare Industry: Biotech Market Cap: $827.25M Activated in VL: True Average Daily Range Avg Daily Range: $0.13 | 3.52% Avg Daily Range (30 D): $0.07 | 2.43% Avg Daily Range (90 D): $0.07 | 2.31% Institutional Daily Volume Avg Daily Volume: 2.68M Avg Daily Volume (30 D): 2.26M Avg Daily Volume (90 D): 3M Trade Size Avg Trade Size (Sh.): 304 Avg Trade Size (Sh.) (30 D): 229 Avg Trade Size (Sh.) (90 D): 231 Institutional Trades Total Inst.Trades: 982 Avg Inst. Trade: $1.65M Avg Inst. Trade (30 D): $1.65M Avg Inst. Trade (90 D): $1.6M Avg Inst. Trade Volume: .46M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.58M Avg Closing Trade (30 D): $1.62M Avg Closing Trade (90 D): $1.7M Avg Closing Volume: 464.54K     News Jul 8, 2025 @ 12:00 PM Akebia Therapeutics to Present at the H.C. Wainwri... Source: Mercedes Carrasco Jun 16, 2025 @ 10:00 AM AVEROA receives European marketing authorization f... Source: N/A May 28, 2025 @ 12:00 PM Akebia Therapeutics to Present at the Jefferies Gl... Source: N/A Apr 2, 2025 @ 9:00 AM AVEROA Receives Positive Opinion from the European... Source: N/A Mar 20, 2025 @ 2:17 AM Akebia Therapeutics Announces Pricing of Public Of... Source: N/A Financials   TTM Q2 2025 Q1 2025 Basic EPS $-.18 $ $.03 Diluted EPS $-.19 $ $.03 Revenue $ 203.73M $ 62.47M $ 57.34M Gross Profit $ 151.66M $ 52.55M $ 49.71M Net Income / Loss $ -36.48M $ .25M $ 6.11M Operating Income / Loss $ .79M $ 14.09M $ 13.51M Cost of Revenue $ 52.07M $ 9.92M $ 7.63M Net Cash Flow $ 97.83M $ 23.94M $ 61.51M PE Ratio